The present description relates to the use of a SRSF3 agent for regulating the function of a myeloid cell, such as a microglial cell and/or monocyte, for treating neurological conditions, cancers, bacterial infections and viral infections wherein the SRSF3 agent inhibits expression or function of SRSF3.

Disclosed herein are methods of eliciting an immune response against a polyomavirus (for example, BKV serotype I (BKV-I), BKV serotype II (BKV-II), BKV serotype III (BKV-III) and/or BKV serotype IV (BKV-IV)) and methods of treating or inhibiting polyomavirus-associated pathology (such as polyomavirus-associated nephropathy, BKV-associated hemorrhagic cystitis, or JC virus-associated progressive multifocal leukoencephalopathy; PML). Further disclosed are immunogenic compositions of use in the disclosed methods. Also disclosed are methods of selecting an organ transplant donor and/or recipient including detecting whether the prospective donor and/or recipient has BKV serotype-specific (such as BKV serotype IV-specific) neutralizing antibodies.

Management of the health status of an animal colony using a plurality of blood collection cards and the analysis of dried blood from members of the colony that has been collected on the cards. Members of the colony may be removed from the colony as a result of the analysis.

A new monoclonal antibody targeting the VP-1 protein of the capsid of the BK polyomavirus, fragments thereof, and uses of same for detecting infection with the BK polyomavirus. The monoclonal antibody is capable of recognizing at least all serotypes Ia, Ib2, II, III and IV of the VP-1 protein of the BK polyomavirus.

The present disclosure is directed to antibodies binding to human respiratory syncytial virus F protein, including both neutralizing and non-neutralizing antibodies, and methods for use thereof.

A biosensor for detecting an influenza A virus in a sample is disclosed, which includes: an influenza A virus antibody immobilized on a surface of Au—Fe.sub.3O.sub.4 composite; where the antibody binds with the influenza A virus in the sample, which converts 4-methylumbelliferyl-N-acetyl-α-D-neuraminic acid (MUNANA) to 4-methylumbelliferone (4-MU), where the 4-MU emits green light at pH of 5.5-6.5; and wherein the 4-MU emits blue light at pH of 9.3-11.3. In the biosensor, 1,1′-oxalyldiimidazole chemiluminescence (ODI-CL) reagent may be utilized to emit the blue and green lights.

Disclosed are a recombinant RBD protein of SARS-CoV-2, and a method for preparing the same. The recombinant RBD protein has a signal polypeptide sequence, an RBD protein sequence, a transmembrane domain sequence and a tag sequence in order from N-terminus to C-terminus. The recombinant RBD protein may be expressed on cell membranes, which facilitates protein stability, enrichment and detection.

Provided is an electrode for electrochemical measurement for detecting or quantitatively determining a target substance, the electrode comprising: a complex supported on a surface of the electrode, wherein the complex is a complex comprising a probe for the target substance, a quantum dot which binds to the probe and is doped with nitrogen and sulfur, and a conductive polymer nanowire in which a metal nanoparticle is embedded.

CRISPR-based diagnostic methods and compositions are provided. One embodiment provides the use of DNA-barcoded antibodies or peptide-MHC (pMHC) tetramers (e.g., Kb-OVA.sub.257-264, Db-GP100.sub.25-33, Db-GP.sub.33-41) and CRISPR-Cas protein, and a guided DNA endonuclease, to achieve ultrasensitive detection of soluble and cell surface proteins. The disclosed embodiments can use type V: Cas12a; type VI: Cas13a, or Cas13b. Combining DNA encoding with CRISPR-Cas protein recognition is a sensitive system because barcodes can be isothermally amplified and Cas, for example Cas12a, enzymatically cleaves DNA reporters upon barcode detection, providing two rounds of amplification and enabling measurement of protein concentration by sample fluorescence or using by paper-based assays. This platform enables monitoring of protein and cellular biomarkers and further expands the toolbox of CRISPR/Cas-based technologies

A device for receiving a digital reader and a lateral flow assay (LFA) cartridge and systems incorporating the same are provided. Aspects of the device include a body having a frame configured to receive the digital reader and a base plate having one or more LFA cartridge receiving positions for positioning one or more LFA cartridges at a fixed orientation relative to a planar space defined by the frame. Also provided are methods for using the device to read a result indicative of the presence or absence of an analyte in a sample.